TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.27 USD
+0.09 (1.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.13 -0.14 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.27 USD
+0.09 (1.25%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.13 -0.14 (-1.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
by Zacks Equity Research
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
Wall Street Analysts See a 215% Upside in TScan Therapeutics, Inc. (TCRX): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 214.5% in TScan Therapeutics, Inc. (TCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.